Third-line or fourth-line chemotherapy in non-small-cell lung cancer patients with relatively good performance status

Yuh Min Chen, Jen Fu Shih, Wen Chien Fan, Chieh Hung Wu, Kun Ta Chou, Chun Ming Tsai, Yu Chin Lee, Reury Perng Perng, Jacqueline Whang-Peng

    Research output: Contribution to journalArticle

    13 Citations (Scopus)

    Abstract

    Background: Our aim here was to explore treatment efficacy of pemetrexed and docetaxel in non-small-cell lung cancer patients who had failed previous chemotherapy and epidermal growth factor receptor-tyrosine kinase inhibitor therapy. Methods: We retrospectively reviewed clinical data of our non-small-cell lung cancer patients who received third- or fourth-line chemotherapy with pemetrexed or docetaxel in our institution from January 2006 to December 2009. Results: One hundred and twenty-three patients received treatment, including 85 patients with pemetrexed treatment and 38 patients with docetaxel treatment. There was no difference in tumor response rate and toxicity profiles when using pemetrexed as third- or fourth-line treatment, neither was there difference in docetaxel treatment of third- versus fourth-line treatment. There was also no difference between docetaxel and pemetrexed in response rate and control rate when they were used as fourth-line treatment. However, docetaxel used in fourth-line treatment had higher incidence of neutropenia and more frequent need of granulocyte colony-stimulating factor support compared with pemetrexed in fourth-line treatment. Median progression-free survivals (PFSs) were 2.6 months and 3.8 months when using pemetrexed as third- and fourth-line treatment, respectively (p = 0.417). Median PFSs were 3.8 months and 4.8 months when using docetaxel as third- and fourth-line treatment, respectively (p = 0.882). There was also no difference in PFS between pemetrexed and docetaxel, both in third- and fourth-line treatment. Median survivals were 13.4, 12.2, 13.2, and 13 months for pemetrexed in third-line, fourth-line, and docetaxel in third-line and fourth-line treatment, respectively. Conclusion: This retrospective study of pemetrexed and docetaxel showed relatively safe toxicity profile, reasonable response rate, and long survival when used as third- and fourth-line chemotherapy. Thus, it is reasonable to give good performance status patients third- and fourth-line chemotherapy. A phase III randomized trial is needed for better clarification of these issues.

    Original languageEnglish
    Pages (from-to)209-214
    Number of pages6
    JournalJournal of the Chinese Medical Association
    Volume74
    Issue number5
    DOIs
    Publication statusPublished - May 2011

    Fingerprint

    docetaxel
    Pemetrexed
    Non-Small Cell Lung Carcinoma
    Drug Therapy
    Therapeutics
    Disease-Free Survival

    Keywords

    • Adenocarcinoma
    • Chemotherapy
    • Docetaxel
    • Non-small-cell lung cancer
    • Pemetrexed

    ASJC Scopus subject areas

    • Medicine(all)

    Cite this

    Third-line or fourth-line chemotherapy in non-small-cell lung cancer patients with relatively good performance status. / Chen, Yuh Min; Shih, Jen Fu; Fan, Wen Chien; Wu, Chieh Hung; Chou, Kun Ta; Tsai, Chun Ming; Lee, Yu Chin ; Perng, Reury Perng; Whang-Peng, Jacqueline.

    In: Journal of the Chinese Medical Association, Vol. 74, No. 5, 05.2011, p. 209-214.

    Research output: Contribution to journalArticle

    Chen, Yuh Min ; Shih, Jen Fu ; Fan, Wen Chien ; Wu, Chieh Hung ; Chou, Kun Ta ; Tsai, Chun Ming ; Lee, Yu Chin ; Perng, Reury Perng ; Whang-Peng, Jacqueline. / Third-line or fourth-line chemotherapy in non-small-cell lung cancer patients with relatively good performance status. In: Journal of the Chinese Medical Association. 2011 ; Vol. 74, No. 5. pp. 209-214.
    @article{a3917794e77943659d4b03776a9bad2f,
    title = "Third-line or fourth-line chemotherapy in non-small-cell lung cancer patients with relatively good performance status",
    abstract = "Background: Our aim here was to explore treatment efficacy of pemetrexed and docetaxel in non-small-cell lung cancer patients who had failed previous chemotherapy and epidermal growth factor receptor-tyrosine kinase inhibitor therapy. Methods: We retrospectively reviewed clinical data of our non-small-cell lung cancer patients who received third- or fourth-line chemotherapy with pemetrexed or docetaxel in our institution from January 2006 to December 2009. Results: One hundred and twenty-three patients received treatment, including 85 patients with pemetrexed treatment and 38 patients with docetaxel treatment. There was no difference in tumor response rate and toxicity profiles when using pemetrexed as third- or fourth-line treatment, neither was there difference in docetaxel treatment of third- versus fourth-line treatment. There was also no difference between docetaxel and pemetrexed in response rate and control rate when they were used as fourth-line treatment. However, docetaxel used in fourth-line treatment had higher incidence of neutropenia and more frequent need of granulocyte colony-stimulating factor support compared with pemetrexed in fourth-line treatment. Median progression-free survivals (PFSs) were 2.6 months and 3.8 months when using pemetrexed as third- and fourth-line treatment, respectively (p = 0.417). Median PFSs were 3.8 months and 4.8 months when using docetaxel as third- and fourth-line treatment, respectively (p = 0.882). There was also no difference in PFS between pemetrexed and docetaxel, both in third- and fourth-line treatment. Median survivals were 13.4, 12.2, 13.2, and 13 months for pemetrexed in third-line, fourth-line, and docetaxel in third-line and fourth-line treatment, respectively. Conclusion: This retrospective study of pemetrexed and docetaxel showed relatively safe toxicity profile, reasonable response rate, and long survival when used as third- and fourth-line chemotherapy. Thus, it is reasonable to give good performance status patients third- and fourth-line chemotherapy. A phase III randomized trial is needed for better clarification of these issues.",
    keywords = "Adenocarcinoma, Chemotherapy, Docetaxel, Non-small-cell lung cancer, Pemetrexed",
    author = "Chen, {Yuh Min} and Shih, {Jen Fu} and Fan, {Wen Chien} and Wu, {Chieh Hung} and Chou, {Kun Ta} and Tsai, {Chun Ming} and Lee, {Yu Chin} and Perng, {Reury Perng} and Jacqueline Whang-Peng",
    year = "2011",
    month = "5",
    doi = "10.1016/j.jcma.2011.03.005",
    language = "English",
    volume = "74",
    pages = "209--214",
    journal = "Journal of the Chinese Medical Association",
    issn = "1726-4901",
    publisher = "Elsevier Taiwan LLC",
    number = "5",

    }

    TY - JOUR

    T1 - Third-line or fourth-line chemotherapy in non-small-cell lung cancer patients with relatively good performance status

    AU - Chen, Yuh Min

    AU - Shih, Jen Fu

    AU - Fan, Wen Chien

    AU - Wu, Chieh Hung

    AU - Chou, Kun Ta

    AU - Tsai, Chun Ming

    AU - Lee, Yu Chin

    AU - Perng, Reury Perng

    AU - Whang-Peng, Jacqueline

    PY - 2011/5

    Y1 - 2011/5

    N2 - Background: Our aim here was to explore treatment efficacy of pemetrexed and docetaxel in non-small-cell lung cancer patients who had failed previous chemotherapy and epidermal growth factor receptor-tyrosine kinase inhibitor therapy. Methods: We retrospectively reviewed clinical data of our non-small-cell lung cancer patients who received third- or fourth-line chemotherapy with pemetrexed or docetaxel in our institution from January 2006 to December 2009. Results: One hundred and twenty-three patients received treatment, including 85 patients with pemetrexed treatment and 38 patients with docetaxel treatment. There was no difference in tumor response rate and toxicity profiles when using pemetrexed as third- or fourth-line treatment, neither was there difference in docetaxel treatment of third- versus fourth-line treatment. There was also no difference between docetaxel and pemetrexed in response rate and control rate when they were used as fourth-line treatment. However, docetaxel used in fourth-line treatment had higher incidence of neutropenia and more frequent need of granulocyte colony-stimulating factor support compared with pemetrexed in fourth-line treatment. Median progression-free survivals (PFSs) were 2.6 months and 3.8 months when using pemetrexed as third- and fourth-line treatment, respectively (p = 0.417). Median PFSs were 3.8 months and 4.8 months when using docetaxel as third- and fourth-line treatment, respectively (p = 0.882). There was also no difference in PFS between pemetrexed and docetaxel, both in third- and fourth-line treatment. Median survivals were 13.4, 12.2, 13.2, and 13 months for pemetrexed in third-line, fourth-line, and docetaxel in third-line and fourth-line treatment, respectively. Conclusion: This retrospective study of pemetrexed and docetaxel showed relatively safe toxicity profile, reasonable response rate, and long survival when used as third- and fourth-line chemotherapy. Thus, it is reasonable to give good performance status patients third- and fourth-line chemotherapy. A phase III randomized trial is needed for better clarification of these issues.

    AB - Background: Our aim here was to explore treatment efficacy of pemetrexed and docetaxel in non-small-cell lung cancer patients who had failed previous chemotherapy and epidermal growth factor receptor-tyrosine kinase inhibitor therapy. Methods: We retrospectively reviewed clinical data of our non-small-cell lung cancer patients who received third- or fourth-line chemotherapy with pemetrexed or docetaxel in our institution from January 2006 to December 2009. Results: One hundred and twenty-three patients received treatment, including 85 patients with pemetrexed treatment and 38 patients with docetaxel treatment. There was no difference in tumor response rate and toxicity profiles when using pemetrexed as third- or fourth-line treatment, neither was there difference in docetaxel treatment of third- versus fourth-line treatment. There was also no difference between docetaxel and pemetrexed in response rate and control rate when they were used as fourth-line treatment. However, docetaxel used in fourth-line treatment had higher incidence of neutropenia and more frequent need of granulocyte colony-stimulating factor support compared with pemetrexed in fourth-line treatment. Median progression-free survivals (PFSs) were 2.6 months and 3.8 months when using pemetrexed as third- and fourth-line treatment, respectively (p = 0.417). Median PFSs were 3.8 months and 4.8 months when using docetaxel as third- and fourth-line treatment, respectively (p = 0.882). There was also no difference in PFS between pemetrexed and docetaxel, both in third- and fourth-line treatment. Median survivals were 13.4, 12.2, 13.2, and 13 months for pemetrexed in third-line, fourth-line, and docetaxel in third-line and fourth-line treatment, respectively. Conclusion: This retrospective study of pemetrexed and docetaxel showed relatively safe toxicity profile, reasonable response rate, and long survival when used as third- and fourth-line chemotherapy. Thus, it is reasonable to give good performance status patients third- and fourth-line chemotherapy. A phase III randomized trial is needed for better clarification of these issues.

    KW - Adenocarcinoma

    KW - Chemotherapy

    KW - Docetaxel

    KW - Non-small-cell lung cancer

    KW - Pemetrexed

    UR - http://www.scopus.com/inward/record.url?scp=79955595767&partnerID=8YFLogxK

    UR - http://www.scopus.com/inward/citedby.url?scp=79955595767&partnerID=8YFLogxK

    U2 - 10.1016/j.jcma.2011.03.005

    DO - 10.1016/j.jcma.2011.03.005

    M3 - Article

    C2 - 21550007

    AN - SCOPUS:79955595767

    VL - 74

    SP - 209

    EP - 214

    JO - Journal of the Chinese Medical Association

    JF - Journal of the Chinese Medical Association

    SN - 1726-4901

    IS - 5

    ER -